Buy & Sell New York Times Co (NYT) – New York Times Co Price Today
Aura AI Summary
Key Stats
- $12.14BMarket Cap
- MediaSector
- -13.51%3M Drawdown
- $11.53BEnterprise Value
- 1.23%Dividend Yield
- 82 daysTypical Hold Time
New York Times Co (NYT) is currently valued at a market capitalization of $12.14B, with an enterprise value of $11.53B. Over the past 52 weeks, New York Times Co has traded between a low of $51.43 and a high of $85.86, highlighting its annual price range. Over the past three months, New York Times Co has recorded a drawdown of -13.51%, reflecting recent price volatility. New York Times Co offers a dividend yield of 1.23%, with the most recent dividend of $0.23 paid on 01 Apr 26. On average, investors hold New York Times Co for approximately 82 days, indicating typical investor behavior on the platform.
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Most Recent News
Emerson Electric partners with Aramco to develop advanced corrosion monitoring systems.
Emerson Electric announced a collaboration with Saudi Aramco to co-develop next-generation corrosion management solutions using ultrasonic online monitoring and wireless technology. This partnership aims to improve operational safety and performance ...
Modern inflation differs from the 1970s, driven by supply issues, not wage-price spirals.
Current inflation trends in the U.S. are often compared to the 1970s stagflation, but experts highlight key differences. Unlike the 1970s, today's inflation is driven mainly by supply-side pressures such as rising commodity prices and geopolitical te...
Atea Pharma shows low drug interaction risk for new Hepatitis C treatment and promising Hepatitis E antiviral data.
Atea Pharmaceuticals announced Phase 1 results indicating their Hepatitis C treatment regimen, combining bemnifosbuvir and ruzasvir, has a low risk of drug-drug interactions with common medications like omeprazole and rosuvastatin. This supports easi...